Evidence map›Paper›PMID 40871671›Full record

Trial reportNutrients2025

Anti-Inflammatory, Antithrombotic and Antioxidant Efficacy and Synergy of a High-Dose Vitamin C Supplement Enriched with a Low Dose of Bioflavonoids; In Vitro Assessment and In Vivo Evaluation Through a Clinical Study in Healthy Subjects.

Vasiliki Chrysikopoulou, Aikaterini Rampaouni, Eleni Koutsia, Anna Ofrydopoulou, Nikolaos Mittas, Alexandros Tsoupras

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07784166 (Study of the Anti-Inflammatory Health Benefits of "Argilos Extra Virgin Olive Oil"), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07784166 naactive not recruitingnot on this map

Study of the Anti-Inflammatory Health Benefits of "Argilos Extra Virgin Olive Oil" ("Healthy Argiloil")

TypeinterventionalSponsorDemocritus University of ThraceRan2025 to 2026Enrolled54ConditionsAntiplatelet, Antithrombotic, Anti-Inflammatory Agents, Non-SteroidalArmsOlive Oil 1, Olive oil (placebo) 1, Olive Oil 2, Olive oil (placebo) 2
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasiliki ChrysikopoulouHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.ORCID 0009-0004-8955-3484
Aikaterini RampaouniHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.
Eleni KoutsiaHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.
Anna OfrydopoulouHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.ORCID 0000-0003-3925-6284
Nikolaos MittasHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.ORCID 0000-0003-3061-7864
Alexandros TsouprasHephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace, St. Lucas, 65404 Kavala, Greece.ORCID 0000-0002-0837-9778

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesVitamin C is frequently used in several dietary supplements due to its proposed health-promoting properties, while phenolic compounds and especially flavonoids have been suggested to provide synergistic antioxidant and cardiovascular benefits. However, the specific interactions between these compounds and their individual contributions to biological activity remain underexplored. This study aimed to evaluate the antioxidant potential and anti-inflammatory and antiplatelet biological effects of a high-dose (1 g) vitamin C-low-dose (50 mg) bioflavonoid (VCF)-based supplement using both in vitro and in vivo approaches in human platelets.

methodsTotal phenolic content was quantified and antioxidant capacity was assessed using DPPH, FRAP, and ABTS assays and compared to individual phenolic standard compounds, including (simple phenolics like gallic acid, flavonoids like quercetin and catechin, and polyphenols like curcumin and tannin), and a standard supplement containing only high-dose vitamin C (VC). ATR-FTIR spectroscopy was used to assess molecular interactions between vitamin C and flavonoids. In vitro anti-inflammatory and antiplatelet activities of all supplements and standards were assessed by quantifying their IC

resultsFrom all phenolic standards, the flavonoids and especially a mixture of flavonoids (catechin + quercetin) showed higher in vitro antioxidant capacity and anti-inflammatory and antiplatelet efficacy, followed by polyphenols and then simple phenolics. The VCF supplement showed the most potent antioxidant capacity, but also the strongest anti-inflammatory and antiplatelet activities too, in comparison to the VC and the mixture of flavonoids, suggesting higher synergy and thus bio-efficacy as a result of the co-presence of flavonoids and vitamin C in this supplement. Platelet reactivity decreased over time for PAF and thrombin in both arms of the trial, but no significant differences were observed between treatment groups, suggesting that the number of flavonoids used was not sufficient to translate the in vitro findings to the in vivo setting.

conclusionsVC-containing supplements provide antioxidant, anti-inflammatory, and antiplatelet benefits, while the incorporation of flavonoids may provide synergistic health benefits, but more in vivo assessment is needed to fully evaluate the dose efficacy.

Indexed as

Anti-Inflammatory AgentsAntioxidantsAscorbic AcidDietary SupplementsFibrinolytic AgentsFlavonoidsAdultBlood PlateletsDrug SynergismFemaleHealthy VolunteersHumansMalePlatelet AggregationPlatelet Aggregation InhibitorsYoung AdultAnti-Inflammatory AgentsAntioxidantsAscorbic AcidFibrinolytic AgentsFlavonoidsPlatelet Aggregation Inhibitorsanti-inflammatoryantioxidant activitybioflavonoidscancer preventioncardiovascular diseasechronic inflammationflavonoidsphenolic compoundssynergistic interactionvitamin C

Identifiers

PMID40871671
PMCPMC12389177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.